DOI:
10.1055/s-00000009
American Journal of Perinatology
LinksClose Window
References
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics 1998;
102 (3, pt. 1): 531-537
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.